Compass Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated May 31, 2022, discloses the results of the Annual Meeting of Stockholders held by Compass Therapeutics, Inc. (CMPX) on that date. The Company is incorporated in Delaware and trades on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The stockholders voted on two primary proposals:
- Proposal 1: Election of Directors
- Philip J. Ferneau: Elected with 57,017,703 votes For, 8,515,732 Withheld, and 16,857,099 Broker Non-votes.
- Carl L. Gordon: Elected with 55,537,796 votes For, 9,995,639 Withheld, and 16,857,099 Broker Non-votes.
- Both directors were elected to serve until the 2025 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of CohnReznick, LLP as the independent registered public accounting firm for the year ending December 31, 2022.
- Votes: 82,319,178 For, 65,654 Against, 5,702 Abstained, and 0 Broker Non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. For detailed descriptions of the proposals, the Company refers investors to its definitive proxy statement on Form DEF 14A filed on April 28, 2022.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the Form DEF 14A (filed April 28, 2022) for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the Company's status as an emerging growth company (indicated as yes in the filing) and its implications for financial reporting.